Drug intelligence / Profile preview

ASP-1001

Development stage: Phase 3
Lead developer: Fortress Biotech
Modality: Small Molecules
Administration: Intranasal

Overview

ASP-1001 is a small molecule drug that was developed by Asphelia Pharmaceuticals as a contrast media formulation nasal spray for the treatment of allergic rhinitis. It was classified as an antiallergic agent, but its precise mechanism of action remains undefined. The drug reached Phase 2/3 clinical trials for allergic rhinitis but development was discontinued and it is not approved or marketed for any indication.

Other names: asp 1001asp1001asp-1001

Beyond the preview

Go deeper on ASP-1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASP-1001.

Explore the full profile